Esh newsletters a manolis

European Society of Hypertension Scientific Newsletter:Update on Hypertension Management HYPERTENSION AND SEXUAL DYSFUNCTION
Athanasios J. Manolis, Cardiology Department, Asklepeion Voula Hospital, Athens, Greece; Michael Doumas, Department of Internal Medici-
ne, University of Thrace, Alexandroupolis, Greece; Margus Viigimaa, Centre of Cardiology, North Estonia Medical Centre, Tallinn, Estonia;
Krzysztof Narkiewicz, Department of Hypertension and Diabetology, Medical University of Gdańsk, Poland

Sexual dysfunction represents a common condition in the general pop- ods used for erectile function assessment are not appropriate [1, 14– ulation placing a major burden on patients’ and their sexual partners’ –16]. Thus, we believe that only a multinational study all over Eu- quality of life. Sexual dysfunction has been traditionally attributed to rope, with accurate blood pressure measurement, careful recording psychogenic origins and managed by mental health professionals and of all concomitant conditions, and use of a validated method (the urologists. However, advances in pathophysiology research point to International Index for Erectile Function, IIEF) could precisely evalu- a vascular origin of the problem in the majority of patients, possibly ate the prevalence of erectile dysfunction in hypertensive patients.
due to atherosclerotic lesions in the genital arteries that result in de-creased blood flow. In addition, the discovery of phosphodiesterase-5 Physiology and pathophysiology
inhibitors has produced an easily available effective treatment, and Penile erection is the result of a complex interplay between psycho- nowadays patients seek help from cardiologists, internists and general logical, neurological, hormonal and vascular factors. Since the sym- practitioners in increasing numbers. Physicians skilled in hypertension pathetic nervous system, the intact endothelium and notably nitric management often feel unqualified to deal with sexual problems since oxide have a central role in a successful erection, it is no surprise adequate training regarding sexuality has not been offered in under- or that essential hypertension is related to erectile dysfunction.
in post-graduate training [1]. In our point of view, several important Hypertension induces structural changes in the penile vascu- reasons exist to motivate hypertension specialists to become familiar lature thus decreasing arterial blood inflow, as well as functional with sexual dysfunction, including the following facts: abnormalities like increased sympathetic activity, endothelial dys- • sexual dysfunction can be detected in a significant percentage of function, reduced nitric oxide bioavailability and activation of the hypertensive patients, affecting their quality of life. Since most renin-angiotensin system. All of the above abnormalities may lead patients are reluctant to address this issue, they either remain to impairment of penile vasodilatation, lack of relaxation and subse- untreated or obtain drugs from unauthorized sources (Internet) • sexual dysfunction may be an adverse event of antihypertensive Relation to cardiovascular disease
medications. Since some drug categories may cause sexual dys- Patients with erectile dysfunction have an increased risk of suffering function, a change in drug category may alleviate the symptoms; from asymptomatic severe coronary heart disease [17]; moreover, • phosphodiesterase-5 inhibitors are vasodilators and reduce blood erectile dysfunction correlates with the number of occluded coro- pressure. Although blood pressure reduction is usually modest, nary vessels as assessed by angiography [18]. In addition, it seems some susceptible patients (especially older and sodium-depleted) that erectile dysfunction and coronary heart disease share common risk factors, since erectile dysfunction is more prevalent in individu- • sexual intercourse may be detrimental in high-risk patients, and als with multiple cardiovascular risk factors [19].
patients with untreated, poorly-controlled, accelerated or malig- Based on data demonstrating that the probability of undiag- nant hypertension are considered as high-risk; thus, sexual activi- nosed coronary artery disease is very high in patients with erectile ty has to be deferred until patients’ stabilization and after appro- dysfunction (up to 40%) [20], we believe that erectile dysfunction might priate medical counselling has been obtained; raise the possibility of underlying cardiovascular disease by being one • many patients with hypertension suffer from coronary artery dis- of the first signs thereof. Therefore, erectile dysfunction can be consid- ease or heart failure and are on nitrate treatment. Since PDE-5 ered as an “early diagnostic window” of coronary heart disease.
inhibitors are contraindicated in patients receiving nitrates, andspecial precautions have to be taken, patients must be under Safety of sexual activity in hypertension
According to the Second Princeton Consensus Conference [21], pa- • sexual dysfunction can be considered as an early sign of wide- tients with controlled hypertension are considered low-risk patients spread atherosclerotic disease in other vascular beds as well.
and may safely proceed with sexual intercourse, since sexual activity Thus, its detection offers an opportunity for early recognition of in such patients doubles the extremely low risk of a cardiac event.
atherosclerotic lesions in other sites (coronary vessels, brain, kid- On the contrary, high-risk patients have a 10-fold increased risk of ney, peripheral arteries) through thorough investigation.
cardiac event during sexual intercourse as well as in the followingtwo hours. Since patients with untreated, poorly controlled, acceler- Definition and prevalence
ated, or malignant hypertension are considered high-risk patients, Erectile dysfunction is defined as the persistent inability to attain and/ sexual activity should be deferred until their condition has been /or maintain penile erection sufficient for sexual intercourse. It has stabilized or a decision has been made by a cardiologist that sexual been recently estimated that over 150 million men all over the world activity may be safely resumed [21].
have some degree of erectile dysfunction, while the projection for thepatient population in 2025 is 322 million men worldwide. The preva- Quality of life
lence of erectile dysfunction in the general population varies markedly Erectile dysfunction compromises overall quality of life, exerting among different countries, ranging from 15% in Brazil to 74% in a major impact on patients’ social and psychological well-being [22].
Finland, probably reflecting different sample populations and assess- Moreover, it adversely affects patients’ sexual partners’ interest in sex ment methods, as well as cultural and religious differences in discuss- and their quality of life [23], thus resulting in the loss of emotional and ing and accepting such a social stigma [2–12].
physical intimacy for both of them (sometimes even leading to divorce).
The vast majority of available data indicates that erectile dys- function is more frequent in patients with essential hypertension Effects of antihypertensive drug therapy
when compared to normotensive subjects, irrespective of the meth- Although essential hypertension is related to erectile dysfunction, an od used for erectile dysfunction evaluation. Severity and duration of important issue has been raised as to whether this represents hypertension, age and antihypertensive treatment seem to be major a result of hypertension per se, of antihypertensive treatment, or determinants of erectile dysfunction in hypertensive patients [13].
However, available data on hypertension is not of the highest Erectile dysfunction is considered an adverse drug event in quality, showing pronounced prevalence variation (26–79%) and one out of five cases [25]. Antihypertensive agents represent one of sometimes relying on self-reporting of hypertension without valida- the most implicated drug classes [25], and hypertensives who expe- tion of medical records; furthermore, the cohorts seem highly-select- rience erectile dysfunction (real or perceived) become non-adherent ed in some studies without reporting co-morbidities, and the meth- to treatment and usually discontinue drugs.
Available data clearly demonstrate that older antihypertensive inability to achieve an orgasm and/or the feeling of pain during drugs exert negative effects on erectile function. In detail, centrally- sexual intercourse (dyspareunia) [38]. Most women exhibit a combi- acting antihypertensives, diuretics and beta-blockers have been re- nation of abnormalities in these four aspects of female sexuality lated to erectile dysfunction, and many patients experience erectile dysfunction as a consequence of treatment with these drugs [26– Female sexuality is markedly under-investigated compared –28]. Although data regarding ACE-inhibitors and calcium antago- to its male counterpart for several reasons: a) female perceptions nists are not quantitatively and qualitatively adequate, they point about sex are much more complicated; b) the physiology and patho- towards a neutral effect of these drugs on erectile function [24]. On physiology of female sexual function remain largely unclarified; c) the contrary, available data for alpha-blockers and especially for no firm, objective measures of female sexual dysfunction exist; and angiotensin receptor antagonists suggest that these drugs may have d) so far, no effective therapy is available.
beneficial effects on erectile function [24, 29–32]. However, we be- It came as a big surprise when the US National Health and Social lieve that large, randomized trials, examining specifically erectile Life Survey reported that female rather than male sexual dysfunction is function, are needed to demonstrate clearly the effect of the differ- more frequent [2]; several subsequent reports have confirmed this find- ing and attracted scientific interest in this topic [39–41]. However, Although the Second Princeton Consensus [21] states that available data regarding the relation between essential hypertension a change in class of antihypertensive drugs rarely results in the and female sexual dysfunction are far from conclusive [14, 41, 42]; restoration of sexual function, data from open studies challenge this nevertheless, most evidence points to a higher prevalence of sexual statement indicating that a switch to angiotensin receptor blockers dysfunction in hypertensive women when compared to normotensive [29–31] or specific beta-blockers (nebivolol) [33] may reverse erectile women. In a study of 417 hypertensive and normotensive women, dysfunction in hypertensive patients taking drugs from other class- increasing systolic blood pressure, increasing age and beta-blocker ad- es. Thus, it seems that a switch to angiotensin receptor blockers ministration were significant predictors of female sexual dysfunction, might prove to be an effective approach for hypertensive men with while success in controlling blood pressure was related to a lower erectile dysfunction while on other antihypertensive agents, before prevalence of sexual dysfunction in hypertensive women [41].
administrating a phosphodiesterase-5 (PDE-5) inhibitor [24].
The relative lack of data in this field implies that specific studies with appropriate methods (Female Sexual Function Index, FSFI) have PDE-5 inhibitors in hypertensive patients
not been performed, rather than suggesting that hypertensive wom- Although all available PDE-5 inhibitors (sildenafil, tadalafil, vardena- en do not experience sexual problems. We believe that despite the lag fil) may cause hypotension through increased nitric oxide bioavail- in female sexual dysfunction research, intense efforts to clarify the ability, and despite the statement of the American Heart Association pathophysiology of female sexual dysfunction will lead to the devel- (in 1999) indicating that sildenafil could be “potentially hazardous” opment of effective treatment modalities; moreover, its relationship in hypertensive patients taking complicated, multi-drug regimens to essential hypertension needs further verification, along with the [34], recent clinical data nonetheless clearly demonstrate that PDE-5 effect of antihypertensive treatment upon its appearance.
inhibitors may be safely co-administered with all classes of antihy-pertensive drugs, even in patients receiving multiple antihyperten- Closing remarks
In conclusion, sexual dysfunction is more prevalent in hypertensive The only class that need special precautionary measures are than in normotensive individuals. Erectile dysfunction may be the alpha-blockers; although, even these drugs are not absolutely con- first sign of asymptomatic coronary heart disease and contribute to traindicated in hypertensive men taking PDE-5 inhibitors [37]. Since its diagnosis. Older antihypertensive drugs exhibit detrimental ef- some beta-blockers possess simultaneous alpha-blocker properties, fects on sexual function, while the newer drugs have either neutral these drugs should also be used with caution.
or beneficial effects. All classes can be safely co-administered withPDE-5 inhibitors, while special precautions should be taken for Female sexual dysfunction
a-blockers. Finally, in our point of view, hypertension guidelines should Female sexual dysfunction can be defined as the persistent or recur- neither ignore nor superficially address this rather important issue rent decrease in sexual desire or arousal, the difficulty or even the that greatly affects patients’ and their sexual partners’ quality of life.
Doumas M, Douma S. Sexual dysfunction in essential hypertension: Myth or reality? J Clin Kirby M, Jackson G, Betteridge J, et al. Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract 2001; 155: 614–618.
Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States; prevalence and Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Prince- predictors. JAMA 1999; 281: 537–544.
ton Consensus Conference). Am J Cardiol 2005; 96: 313–321.
Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to Althof SE. Quality of life and erectile dysfunction. Urology 2002; 59: 803–810.
69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000; Wagner G, Fugl-Meyer KS, Fugl-Meyer AR. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Imp Res 2000; 12 (suppl 4): S144–S146.
Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the Doumas M, Douma S. The effect of antihypertensive drugs on erectile function: a proposed “Cologne Male Survey”. Int J Impot Res 2000; 12: 305–311.
management algorithm. J Clin Hypertens 2006; 8: 359–364.
Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, et al. Prevalence and independent Keene LC, Davies PH. Drug related erectile dysfunction. Adverse Drug React Toxicol Rev risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001; 166: 569–575.
Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual Mak R, de Backer G, Kornitzer M, et al. Prevalence and correlates of erectile dysfunction in function and quality of life: the TAIM study. Ann Intern Med 1991; 114: 613–620.
a population-based study in Belgium. European Urol 2002; 41: 132–138.
Ko DT, Hebert PR, Coffey CS, et al. B-blocker therapy and symptoms of depression, fatigue, Akkus E, Kadioglou A, Esen A, et al. Prevalence and correlates of erectile dysfunction in and sexual dysfunction. JAMA 2002; 288: 351–357.
Turkey: a population-based study. European Urol 2002; 41: 298–304.
Williams GH, Croog SH, Levine S, et al. Impact of antihypertensive therapy on quality of life: Bacon CG, Mittleman MA, Kawachi I, et al. Sexual function in men older than 50 years of effect of hydrochlorothiazide. J Hypertension 1987; 5 (suppl): S29–S35.
age: results from the Health Professionals Follow-up Study. Ann Intern Med 2003; 139: Llisterri Caro JL, Lozano Vidal JV, Aznar Vicente J, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321: 336–341.
Nicolosi A, Moreira ED Jr, Shirai M, et al. Epidemiology of erectile dysfunction in four coun- Della Chiesa A, Pfifner D, Meier B, et al. Sexual activity in hypertensive men. J Human Hyper- tries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology.
Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hyperten- Shiri R, Koskimaki J, Hakkinen J, et al. Effects of age, comorbidity and lifestyle factors on sive men. Blood Press 2003; 12 (suppl 2): 29–34.
erectile function: Tampere Ageing Male Urological Study (TAMUS). European Urol 2004; Fogari R, Zoppi A, Poletti L, et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001; 14: 27–31.
Ponholzer A, Temml C, Mock K, et al. Prevalence and risk factors for erectile dysfunction in Doumas M, Tsakiris A, Douma S, et al. Beneficial effect of b-blockers switch to nebivolol on 2869 men using a validated questionnaire. European Urol 2005; 47: 80–86.
erectile function in hypertensive patients. Asian Journal of Andrology 2006; 8 (2): 177–182.
Rosen RC, Fischer WA, Eardley I, et al. The multinational Men’s Attitudes to Life Events and Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consensus document. Use of Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/ the general population. Curr Med Res Opin 2004; 20: 607–617.
American Heart Association. J Am Coll Cardiol 1999; 33: 273–282.
Doumas M, Tsakiris A, Douma S, et al. Factors affecting the increased prevalence of erectile Pickering TG, Shepherd AMM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in dysfunction in hypertensive compared to normotensive individuals. J Androl 2005; 27 (3): men receiving multiple antihypertensive agents. A randomised, controlled trial. Am J Hy- Grimm RH, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on com- antihypertensive drugs and nutritional hygienic treatment in hypertensive men and wom- mon antihypertensive therapies. Am J Cardiol 2003; 92 (suppl): 47M–57M.
en: Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29: 8–14.
Montague DK, Jarow JP, Broderick GA, et al. The management of erectile dysfunction: an Aranda P, Ruilope LM, Calvo C, et al. Erectile dysfunction in essential arterial hypertension and American Urologic Association update. J Urology 2005; 174: 230–239.
effects of sildenafil: results of a Spanish national study. Am J Hypertens 2004; 17: 139–145.
Bachman GA, Avci D. Evaluation and management of female sexual dysfunction. The Endo- Ferrario CM, Levy P. Sexual dysfunction in patients with hypertension: implications for ther- apy. J Clin Hypertens 2002; 4: 424–432.
Nusbaum MR, Gamble F, Skinner B, et al. The high prevalence of sexual concerns among Montorsi F, Salonia A, Montorsi P, et al. May erectile dysfunction predict ischemic heart women seeking routine gynecological care. J Fam Pract 2000; 49: 229–232.
disease? J Urol 2002; 167 (suppl): 148–149.
Read S, King M, Watson J. Sexual dysfunction in primary medical care: prevalence, charac- Greenstein A, Chen J, Matzkin H, et al. Does severity of ischaemic coronary disease corre- teristics and detection by the general practitioner. J Public Health Med 1997; 19: 387–391.
late with erectile function? Int J Impotence Res 1997; 9: 123–126.
Doumas M, Tsiodras S, Tsakiris A, et al. Female sexual dysfunction in essential hyperten- Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: sion: a common problem being uncovered. J Hypertens 2006; 24: 2387–2392.
prospective results from the Massachusetts Male Aging Study. Prev Med 2000; 30: 328– Duncan LE, Lewis C, Jenkins P, et al. Does hypertension and its pharmacotherapy affect the quality of sexual function in women? Am J Hypertens 2000; 13: 640–647.


AMSEC - Knowledge Frontier Series April 27, 2010 ‘Indian Pharmaceutical Industry — a prescription for growth’ Expert Speaker: Dr. Bomi Gagrat Executive Director, Pfizer Limited Dr. Bomi Gagrat was expert speaker at AMSEC’s Knowledge Frontier Series held on April 27, 2010. In an enthralling one-hour session on ‘Indian Pharmaceutical Industry — a prescription for growth

Ontario Generic Drug Price Reforms Finalized The Ontario Ministry of Health and Long-Term Care (Ministry) has finalized the significant reforms relating to generic drug pricing first announced on April 7, 2010. The changes have been implemented through amendments to the Drug Interchangeability and Dispensing Fee Act (DIDFA) and the Ontario Drug Benefit Act (ODBA) and their respectiv

Copyright © 2010-2019 Pdf Physician Treatment